Age (gender)

Comorbillities

Drug (Dose)

Clinical Manifestation (Latency)

Treatment (duration)/maintenance

Response (time)

Evolution (time)

Number of prescription drugs

81 (F) 

T2DM, CKD, SAH, HF, COPD,

Linagliptin (5 mg)

Non-bullous phase and bullous phase (4 months)

Drug withdrawal, doxycycline (200 mg/d),

prednisone 30 mg/day (1 year)/Azathioprine (50 mg/day) 

Partial (2 month) 

Chronic (2 years)

6

83 (M)

T2DM, SAH

Linagliptin (5 mg)

Non-bullous phase and bullous phase (1 year)

 Drug withdrawal, prednisone 20 mg/d (1 year) doxycycline (100 mg/day)/prednisone 10 mg

Partial (3 month)

Chronic (2 years)

13

70 (F)

HF, T2DM, HCV, Ampullary cancer

Sitagliptin (100 mg)

Non-bullous phase and bullous phase (1 week)

 Drug withdrawal, prednisone 15 mg/day (on track)

Partial (1 week)

Ontrack

 3

87 (M)

T2DM, dyslipidemia, CKD, HF

Linagliptin (5 mg)

Bullous phase (1 month)

 Drug withdrawal, prednisone 20 mg/day, topic clobetasol lymecycline 150 mg/day

Complete (5 months)

Chronic (5 months)

10